# Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma

> **NCT06583083** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 84 (estimated)

## Conditions studied

- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

## Interventions

- **DRUG:** Sintilimab with P-GEMOX Regimen
- **DRUG:** P-GEMOX Regimen

## Key facts

- **NCT ID:** NCT06583083
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2026-08-28
- **Final completion:** 2026-08-28
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06583083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06583083, "Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06583083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*